Sign in to view content

Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!

David M. Brown, MD

Video
Published 2018

Related

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Open-Label Study Evaluating the Effects of the CCR3 Antagonist ALK4290 in Patients With Neovascular AMD Refractory to Anti-VEGF Therapy
Michael W. Stewart, MD
Annual Meeting Talks
2019
Episode 29: Anti-VEGF Levels in Breast Milk after Intravitreal Injections- Drs. Muni and Juncal
Keyvan Koushan, MD, FRCSC
Member Podcasts

Category: AMD-Neovascular

See more